Type 2 diabetes drug battle on tap

FDA approval for Merck’s Januvia today sets the stage for a major marketing battle in a new class of Type 2 diabetes drugs. Januvia is part of the emerging drug class of DPP-4 inhibitors, which enhance the body's ability to lower elevated blood sugar. Novartis expects to see FDA approval for its DPP-4 drug Galvus by next month. Analysts have predicted sales of over $1 billion for both drugs. Physicians are ready to start prescribing the products right away, according to a survey conducted by Reuters Primary Research, which researches industry issues and trends for institutional investors. In a survey of about 60 endocrinologists, general practitioners and internists -- who already had at least some awareness of the drugs -- virtually all said they would use either Januvia or Galvus alone or in combination with other treatments. Of those physicians, about 90% of primary care practitioners said they intend to use Januvia and Galvus, while 95% of endocrinologists said they intended to use them.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions